Episodic ataxia

Last updated
Episodic ataxia
Specialty Nervous system ion channel mutations (Channelopathies)

Episodic ataxia (EA) is an autosomal dominant disorder characterized by sporadic bouts of ataxia (severe discoordination) with or without myokymia (continuous muscle movement). There are seven types recognized but the majority are due to two recognized entities. [1] Ataxia can be provoked by psychological stress or startle, or heavy exertion, including exercise. Symptoms can first appear in infancy. There are at least six loci for EA, of which 4 are known genes. Some patients with EA also have migraine or progressive cerebellar degenerative disorders, symptomatic of either familial hemiplegic migraine or spinocerebellar ataxia. Some patients respond to acetazolamide though others do not.

Contents

Signs and symptoms

Typically, episodic ataxia presents as bouts of ataxia induced by startle, stress, or exertion. Some patients also have continuous tremors of various motor groups, known as myokymia. Other patients have nystagmus, vertigo, tinnitus, diplopia or seizures.[ citation needed ]

Cause

The various symptoms of EA are caused by dysfunction of differing areas. Ataxia, the most common symptom, is due to misfiring of Purkinje cells in the cerebellum. This is either due to direct malfunction of these cells, such as in EA2, or improper regulation of these cells, such as in EA1. Seizures are likely due to altered firing of hippocampal neurons (KCNA1 null mice have seizures for this reason).[ citation needed ]

Pathophysiology

EA1: KCNA1

Figure 1. Schematic structure of KV1.1 with the episodic ataxia type 1 mutations noted in red. EA1.png
Figure 1. Schematic structure of KV1.1 with the episodic ataxia type 1 mutations noted in red.

Type 1 episodic ataxia (EA1) is characterized by attacks of generalized ataxia induced by emotion or stress, with myokymia both during and between attacks. This disorder is also known as episodic ataxia with myokymia (EAM), hereditary paroxysmal ataxia with neuromyotonia and Isaacs-Mertens syndrome. Onset of EA1 occurs during early childhood to adolescence and persists throughout the patient's life. Attacks last from seconds to minutes. Mutations of the gene KCNA1, which encodes the voltage-gated potassium channel KV1.1, are responsible for this subtype of episodic ataxia. KV1.1 is expressed heavily in basket cells and interneurons that form GABAergic synapses on Purkinje cells. The channels aid in the repolarization phase of action potentials, thus affecting inhibitory input into Purkinje cells and, thereby, all motor output from the cerebellum. EA1 is an example of a synaptopathy. There are currently 17 KV1.1 mutations associated with EA1, Table 1 and Figure 1. 15 of these mutations have been at least partly characterized in cell culture based electrophysiological assays wherein 14 of these 15 mutations have demonstrated drastic alterations in channel function. As described in Table 1, most of the known EA1 associated mutations result in a drastic decrease in the amount of current through KV1.1 channels. Furthermore, these channels tend to activate at more positive potentials and slower rates, demonstrated by positive shifts in their V½ values and slower τ activation time constants, respectively. Some of these mutations, moreover, produce channels that deactivate at faster rates (deactivation τ), which would also result in decreased current through these channels. While these biophysical changes in channel properties likely underlie some of the decrease in current observed in experiments, many mutations also seem to result in misfolded or otherwise mistrafficked channels, which is likely to be the major cause of dysfunction and disease pathogenesis. It is assumed, though not yet proven, that decrease in KV1.1 mediated current leads to prolonged action potentials in interneurons and basket cells. As these channels are important in the regulation of Purkinje cell activity, it is likely that this results increased and aberrant inhibitory input into Purkinje cells and, thus, disrupted Purkinje cell firing and cerebellum output.[ citation needed ]

Table 1. Mutations in KCNA1 related to episodic ataxia type-1
MutationPositionCurrent amplitude
(% wild-type)		ActivationDeactivation (τ)OtherReferences
V½τ
V174FS17.6%25mV positiveUnchangedUnchanged [2] , [3] , [4] , [5]
I177NS15.9%60mV positiveSlowerFasterShorter mean open time and smaller single channel conductance [6] , [7]
F184CS115.1%24mV positiveSlowerSlowerFewer channels at membrane [3] , [4] , [5] , [8]
T226AS25%15mV positiveSlowerSlower [6] , [9]
T226MS25%15mV positiveSlowerSlower [5] , [10]
T226RS23% ? ? ? [11]
R239SS20%NANANAImproper trafficking [2] , [4] , [9]
A242PS210%4mV NegativeSlowerSlower [12]
P244HS2-3UnchangedUnchangedUnchangedUnchanged [12]
F249IS2-31%UnchangedUnchangedSlowerImproper trafficking [2] , [4] , [5]
G311SS3-422.9%30mV positiveUnchangedUnchanged [9]
E325DS57.7%52.4mV positiveFasterFasterImpaired translation or stability [3] , [4] , [5] , [13] , [14] , [15]
L329IS5 ? ? ? ? [16]
S342IS5 ? ? ? ? [17]
V404IS6Unchanged12mV positiveSlowerSlower [6] , [12]
V408AC-terminus68%UnchangedFasterFasterShorter mean open time, more and larger sIPSCs in Mice [2] , [4] , [5] , [8] , [13] , [14] , [15] , [18]
R417XC-terminus2%9mV positiveSlowerFasterMisfolds and form membranous aggregates [12] , [19]
Current amplitude refers to the amount of current through mutant versus wild-type channels in cell culture or oocyte assays. Activation V½ is the potential at which the population of channels is half maximally activated which the accompanying τ is the time constant of the populations activation. Deactivation τ is similar to that of activation, referring instead to the time constant of population closing. sIPSCs are spontaneous inhibitory post synaptic currents. Cells with a red background indicate that this property will result in decreased KV1.1 current while cells with a green background indicate increased current through this channel.

EA2: CACNA1A

Figure 2. Schematic structure of CaV2.1 with the episodic ataxia type 2 mutations noted in red. Episodic Ataxia Schematic Structure.png
Figure 2. Schematic structure of CaV2.1 with the episodic ataxia type 2 mutations noted in red.

Type 2 episodic ataxia (EA2) is characterized by acetazolamide-responsive attacks of ataxia with or without migraine. Patients with EA2 may also present with progressive cerebellar atrophy, nystagmus, vertigo, visual disturbances and dysarthria. These symptoms last from hours to days, in contrast with EA1, which lasts from seconds to minutes. Attacks can be accompanied by increased heart rate and blood pressure, moderate to severe shaking, and stuttering. Like EA1, attacks can be precipitated by exercise, emotional stress/agitation, physical stress, or heat (overheated body temperature) but also by coffee and alcohol. EA2 is caused by mutations in CACNA1A, which encodes the P/Q-type voltage-gated calcium channel CaV2.1, and is also the gene responsible for causing spinocerebellar ataxia type-6 and familial hemiplegic migraine type-1. EA2 is also referred to as episodic ataxia with nystagmus, hereditary paroxysmal cerebellopathy, familial paroxysmal ataxia and acetazolamide-responsive hereditary paroxysmal cerebellar ataxia (AHPCA). There are currently 19 mutations associated with EA2, though only 3 have been characterized electrophysiologically, table 2 and figure 2. Of these, all result in decreased current through these channels. It is assumed that the other mutations, especially the splicing and frameshift mutations, also result in a drastic decrease in CaV2.1 currents, though this may not be the case for all mutations. CACNA1A is heavily expressed in Purkinje cells of the cerebellum where it is involved in coupling action potentials with neurotransmitter release. Thus, decrease in Ca2+ entry through CaV2.1 channels is expected to result in decreased output from Purkinje cells, even though they will fire at an appropriate rate. The tottering mouse is a widely used model to study EA2, as it developed a spontaneous homologous mutation in Cacna1a in the early 1960s. [20] Alternatively, some CACNA1A mutations, such as those seen in familial hemiplegic migraine type-1, result in increased Ca2+ entry and, thereby, aberrant transmitter release. This can also result in excitotoxicity, as may occur in some cases of spinocerebellar ataxia type-6.

Table 2. Mutations in CACNA1A related to Episodic ataxia type-2
MutationPositionEffectCerebellar SignsReferences
H253YD1-pore ?Yes [21]
C271Y* D1-poreDecreased maximal current due to protein instabilityYes [22]
G293R* D1-poreDecreased maximal current due to protein instabilityYes [22] , [23]
F624LfsX657D2S5 ?Yes [21]
Q681RfsX780D2-pore ?Yes [21]
S753fsX780D2S6 ?Yes [24]
P1266LfsX1293D3S1 ?Yes [24] , [25]
R1278XD3S1-2 ?Yes [26]
F1391LfsX1429D3S5 ?Yes [21]
Y1443XD3-pore ?Yes [24]
F1490KD3S6No current, though expressedYes [27]
R1546XD4S1 ?Yes [24]
A1593_Y1594delinsDD4S2 ?Yes [24]
R1661HD4S4 ?Yes [28]
R1664Q* D4S4 ?Yes [29]
E1756KD4-pore ?Yes [30]
SplicingIntron 11 ?Yes [24]
SplicingIntron 26 ?Yes [24]
SplicingIntron 28 ?Yes [25]
*
Also diagnosed as Spinocerebellar ataxia type-6

EA3: 1q42

Episodic ataxia type-3 (EA3) is similar to EA1 but often also presents with tinnitus and vertigo. Patients typically present with bouts of ataxia lasting less than 30 minutes and occurring once or twice daily. During attacks, they also have vertigo, nausea, vomiting, tinnitus and diplopia. These attacks are sometimes accompanied by headaches and precipitated by stress, fatigue, movement and arousal after sleep. Attacks generally begin in early childhood and last throughout the patients' lifetime. Acetazolamide administration has proved successful in some patients. [31] As EA3 is extremely rare, there is currently no known causative gene. The locus for this disorder has been mapped to the long arm of chromosome 1 (1q42). [32]

EA4

Also known as periodic vestibulocerebellar ataxia, type-4 episodic ataxia (EA4) is an extremely rare form of episodic ataxia differentiated from other forms by onset in the third to sixth generation of life, defective smooth pursuit and gaze-evoked nystagmus. Patients also present with vertigo and ataxia. There are only two known families with EA4, both located in North Carolina. The locus for EA4 is unknown.[ citation needed ]

EA5: CACNB4

There are two known families with type-5 episodic ataxia (EA5).[ citation needed ]

These patients can present with an overlapping phenotype of ataxia and seizures similar to juvenile myoclonic epilepsy. In fact, juvenile myoclonic epilepsy and EA5 are allelic and produce proteins with similar dysfunction.[ citation needed ]

Patients with pure EA5 present with recurrent episodes of ataxia with vertigo. Between attacks they have nystagmus and dysarthria. These patients are responsive to acetazolamide.

Both juvenile myoclonic epilepsy and EA5 are a result of mutations in CACNB4, a gene that encodes the calcium channel β4 subunit. This subunit coassembles with α-subunits and produces channels that slowly inactivate after opening.[ citation needed ]

EA5 patients have a cysteine to phenylalanine mutation at position 104.[ citation needed ]

Thus results in channels with 30% greater current than wild-type.

As this subunit is expressed in the cerebellum, it is assumed that such increased current results in neuronal hyperexcitability

Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia.

EA6: SLC1A3

Type-6 episodic ataxia (EA6) is a rare form of episodic ataxia, identified initially in a 10-year-old boy who first presented with 30 minute bouts of decreased muscle tone during infancy. He required "balance therapy" as a young child to aid in walking and has a number of ataxic attacks, each separated by months to years. These attacks were precipitated by fever. He has cerebellar atrophy and subclinical seizures. During later attacks, he also presented with distortions of the left hemifield, ataxia, slurred speech, followed by headache. After enrolling in school, he developed bouts of rhythmic arm jerking with concomitant confusion, also lasting approximately 30 minutes. He also has presented, at various times, with migraines. This patient carries a proline to arginine substitution in the fifth transmembrane-spanning segment of the gene SLC1A3. This gene encodes the excitatory amino acid transporter 1 (EAAT1) protein, which is responsible for glutamate uptake. In cell culture assays, this mutation results in drastically decreased glutamate uptake in a dominant-negative manner. This is likely due to decreased synthesis or protein stability. As this protein is expressed heavily in the brainstem and cerebellum, it is likely that this mutation results in excitotoxicity and/or hyperexcitability leading to ataxia and seizures. [33] Mutations in EAAT1 (GLAST) have subsequently been identified in a family with episodic ataxia. [34]

Diagnosis

Treatment

Depending on subtype, many patients find that acetazolamide therapy is useful in preventing attacks. In some cases, persistent attacks result in tendon shortening, for which surgery is required.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Purkinje cell</span> Specialized neuron in the cerebellum

Purkinje cells, or Purkinje neurons, are a class of GABAergic inhibitory neurons located in the cerebellum. They are named after their discoverer, Czech anatomist Jan Evangelista Purkyně, who characterized the cells in 1839.

Familial hemiplegic migraine (FHM) is an autosomal dominant type of hemiplegic migraine that typically includes weakness of half the body which can last for hours, days, or weeks. It can be accompanied by other symptoms, such as ataxia, coma, and paralysis. Migraine attacks may be provoked by minor head trauma. Some cases of minor head trauma in patients with hemiplegic migraine can develop into delayed cerebral edema, a life-threatening medical emergency. Clinical overlap occurs in some FHM patients with episodic ataxia type 2 and spinocerebellar ataxia type 6, benign familial infantile epilepsy, and alternating hemiplegia of childhood.

<span class="mw-page-title-main">Kv1.1</span>

Potassium voltage-gated channel subfamily A member 1 also known as Kv1.1 is a shaker related voltage-gated potassium channel that in humans is encoded by the KCNA1 gene. Isaacs syndrome is a result of an autoimmune reaction against the Kv1.1 ion channel.

<span class="mw-page-title-main">Voltage-gated potassium channel</span> Class of transport proteins

Voltage-gated potassium channels (VGKCs) are transmembrane channels specific for potassium and sensitive to voltage changes in the cell's membrane potential. During action potentials, they play a crucial role in returning the depolarized cell to a resting state.

<span class="mw-page-title-main">Spinocerebellar ataxia type 6</span> Medical condition

Spinocerebellar ataxia type 6 (SCA6) is a rare, late-onset, autosomal dominant disorder, which, like other types of SCA, is characterized by dysarthria, oculomotor disorders, peripheral neuropathy, and ataxia of the gait, stance, and limbs due to cerebellar dysfunction. Unlike other types, SCA 6 is not fatal. This cerebellar function is permanent and progressive, differentiating it from episodic ataxia type 2 (EA2) where said dysfunction is episodic. In some SCA6 families, some members show these classic signs of SCA6 while others show signs more similar to EA2, suggesting that there is some phenotypic overlap between the two disorders. SCA6 is caused by mutations in CACNA1A, a gene encoding a calcium channel α subunit. These mutations tend to be trinucleotide repeats of CAG, leading to the production of mutant proteins containing stretches of 20 or more consecutive glutamine residues; these proteins have an increased tendency to form intracellular agglomerations. Unlike many other polyglutamine expansion disorders expansion length is not a determining factor for the age that symptoms present.

<span class="mw-page-title-main">Spinocerebellar ataxia type-13</span> Medical condition

Spinocerebellar ataxia type 13 (SCA13) is a rare autosomal dominant disorder, which, like other types of SCA, is characterized by dysarthria, nystagmus, and ataxia of gait, stance and the limbs due to cerebellar dysfunction. Patients with SCA13 also tend to present with epilepsy, an inability to run, and increased reflexes. This cerebellar dysfunction is permanent and progressive. SCA13 is caused by mutations in KCNC3, a gene encoding a voltage-gated potassium channel KV3.3. There are two known mutations in this gene causative for SCA13. Unlike many other types of SCA, these are not polyglutamine expansions but, rather, point mutations resulting in channels with no current or altered kinetics.

The P-type calcium channel is a type of voltage-dependent calcium channel. Similar to many other high-voltage-gated calcium channels, the α1 subunit determines most of the channel's properties. The 'P' signifies cerebellar Purkinje cells, referring to the channel's initial site of discovery. P-type calcium channels play a similar role to the N-type calcium channel in neurotransmitter release at the presynaptic terminal and in neuronal integration in many neuronal types.

Ca<sub>v</sub>2.1 Protein-coding gene in the species Homo sapiens

Cav2.1, also called the P/Q voltage-dependent calcium channel, is a calcium channel found mainly in the brain. Specifically, it is found on the presynaptic terminals of neurons in the brain and cerebellum. Cav2.1 plays an important role in controlling the release of neurotransmitters between neurons. It is composed of multiple subunits, including alpha-1, beta, alpha-2/delta, and gamma subunits. The alpha-1 subunit is the pore-forming subunit, meaning that the calcium ions flow through it. Different kinds of calcium channels have different isoforms (versions) of the alpha-1 subunit. Cav2.1 has the alpha-1A subunit, which is encoded by the CACNA1A gene. Mutations in CACNA1A have been associated with various neurologic disorders, including familial hemiplegic migraine, episodic ataxia type 2, and spinocerebellar ataxia type 6.

<span class="mw-page-title-main">Cation channel superfamily</span> Family of ion channel proteins

The transmembrane cation channel superfamily was defined in InterPro and Pfam as the family of tetrameric ion channels. These include the sodium, potassium, calcium, ryanodine receptor, HCN, CNG, CatSper, and TRP channels. This large group of ion channels apparently includes families 1.A.1, 1.A.2, 1.A.3, and 1.A.4 of the TCDB transporter classification.

<span class="mw-page-title-main">KCNA5</span> Protein-coding gene in humans

Potassium voltage-gated channel, shaker-related subfamily, member 5, also known as KCNA5 or Kv1.5, is a protein that in humans is encoded by the KCNA5 gene.

<span class="mw-page-title-main">KCNA2</span> Protein-coding gene in the species Homo sapiens

Potassium voltage-gated channel subfamily A member 2 also known as Kv1.2 is a protein that in humans is encoded by the KCNA2 gene.

<span class="mw-page-title-main">KCNA4</span> Protein-coding gene in the species Homo sapiens

Potassium voltage-gated channel subfamily A member 4 also known as Kv1.4 is a protein that in humans is encoded by the KCNA4 gene. It contributes to the cardiac transient outward potassium current (Ito1), the main contributing current to the repolarizing phase 1 of the cardiac action potential.

<span class="mw-page-title-main">KCNA3</span> Protein-coding gene in the species Homo sapiens

Potassium voltage-gated channel, shaker-related subfamily, member 3, also known as KCNA3 or Kv1.3, is a protein that in humans is encoded by the KCNA3 gene.

Ca<sub>v</sub>1.1 Mammalian protein found in Homo sapiens

Cav1.1 also known as the calcium channel, voltage-dependent, L type, alpha 1S subunit, (CACNA1S), is a protein which in humans is encoded by the CACNA1S gene. It is also known as CACNL1A3 and the dihydropyridine receptor.

<span class="mw-page-title-main">KCNAB1</span> Protein-coding gene in the species Homo sapiens

Voltage-gated potassium channel subunit beta-1 is a protein that in humans is encoded by the KCNAB1 gene.

<span class="mw-page-title-main">KCNAB2</span> Protein-coding gene in the species Homo sapiens

Voltage-gated potassium channel subunit beta-2 is a protein that in humans is encoded by the KCNAB2 gene.

<span class="mw-page-title-main">KCNC3</span> Protein-coding gene in the species Homo sapiens

Potassium voltage-gated channel, Shaw-related subfamily, member 3 also known as KCNC3 or Kv3.3 is a protein that in humans is encoded by the KCNC3.

<span class="mw-page-title-main">KCNA7</span> Protein-coding gene in the species Homo sapiens

Potassium voltage-gated channel subfamily A member 7 also known as Kv1.7 is a protein that in humans is encoded by the KCNA7 gene. The protein encoded by this gene is a voltage-gated potassium channel subunit. It may contribute to the cardiac transient outward potassium current (Ito1), the main contributing current to the repolarizing phase 1 of the cardiac action potential.

<span class="mw-page-title-main">KCNA10</span> Protein-coding gene in the species Homo sapiens

Potassium voltage-gated channel subfamily A member 10 also known as Kv1.8 is a protein that in humans is encoded by the KCNA10 gene. The protein encoded by this gene is a voltage-gated potassium channel subunit.

<span class="mw-page-title-main">KCNAB3</span> Protein-coding gene in the species Homo sapiens

Voltage-gated potassium channel subunit beta-3 is a protein that in humans is encoded by the KCNAB3 gene. The protein encoded by this gene is a voltage-gated potassium channel beta subunit.

References

  1. ↑ Riant F, Vahedi K, Tournier-Lasserve E (2011) Hereditary episodic ataxia. Rev Neurol (Paris)
  2. 1 2 3 4 Browne D, Gancher S, Nutt J, Brunt E, Smith E, Kramer P, Litt M (1994). "Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1". Nat Genet. 8 (2): 136–40. doi:10.1038/ng1094-136. PMID   7842011. S2CID   8573317.
  3. 1 2 3 Browne D, Brunt E, Griggs R, Nutt J, Gancher S, Smith E, Litt M (1995). "Identification of two new KCNA1 mutations in episodic ataxia/myokymia families". Hum Mol Genet. 4 (9): 1671–2. doi:10.1093/hmg/4.9.1671. PMID   8541859.
  4. 1 2 3 4 5 6 Adelman J, Bond C, Pessia M, Maylie J (1995). "Episodic ataxia results from voltage-dependent potassium channels with altered functions". Neuron. 15 (6): 1449–54. doi: 10.1016/0896-6273(95)90022-5 . PMID   8845167. S2CID   15398598.
  5. 1 2 3 4 5 6 Zerr P, Adelman J, Maylie J (1998). "Episodic ataxia mutations in Kv1.1 alter potassium channel function by dominant negative effects or haploinsufficiency". J Neurosci. 18 (8): 2842–8. doi:10.1523/JNEUROSCI.18-08-02842.1998. PMC   6792579 . PMID   9526001.
  6. 1 2 3 Scheffer H, Brunt E, Mol G, van der Vlies P, Stulp R, Verlind E, Mantel G, Averyanov Y, Hofstra R, Buys C (1998). "Three novel KCNA1 mutations in episodic ataxia type I families". Hum Genet. 102 (4): 464–6. doi:10.1007/s004390050722. PMID   9600245. S2CID   1244779.
  7. ↑ Imbrici P, Cusimano A, D'Adamo M, De Curtis A, Pessia M (2003). "Functional characterization of an episodic ataxia type-1 mutation occurring in the S1 segment of hKv1.1 channels". Pflügers Arch. 446 (3): 373–9. doi:10.1007/s00424-002-0962-2. PMID   12799903. S2CID   21478393.
  8. 1 2 Bretschneider F, Wrisch A, Lehmann-Horn F, Grissmer S (1999). "Expression in mammalian cells and electrophysiological characterization of two mutant Kv1.1 channels causing episodic ataxia type 1 (EA-1)". Eur J Neurosci. 11 (7): 2403–12. doi:10.1046/j.1460-9568.1999.00659.x. PMID   10383630. S2CID   7819824.
  9. 1 2 3 Zerr P, Adelman J, Maylie J (1998). "Characterization of three episodic ataxia mutations in the human Kv1.1 potassium channel". FEBS Lett. 431 (3): 461–4. doi: 10.1016/S0014-5793(98)00814-X . PMID   9714564.
  10. ↑ Comu S, Giuliani M, Narayanan V (1996). "Episodic ataxia and myokymia syndrome: a new mutation of potassium channel gene Kv1.1". Ann Neurol. 40 (4): 684–7. doi:10.1002/ana.410400422. PMID   8871592. S2CID   24163870.
  11. ↑ Zuberi S, Eunson L, Spauschus A, De Silva R, Tolmie J, Wood N, McWilliam R, Stephenson J, Kullmann D, Hanna M (1999). "A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy". Brain. 122 (5): 817–25. doi: 10.1093/brain/122.5.817 . PMID   10355668.
  12. 1 2 3 4 Eunson L, Rea R, Zuberi S, Youroukos S, Panayiotopoulos C, Liguori R, Avoni P, McWilliam R, Stephenson J, Hanna M, Kullmann D, Spauschus A (2000). "Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability". Ann Neurol. 48 (4): 647–56. doi:10.1002/1531-8249(200010)48:4<647::AID-ANA12>3.0.CO;2-Q. PMID   11026449. S2CID   1691004.
  13. 1 2 D'Adamo M, Liu Z, Adelman J, Maylie J, Pessia M (1998). "Episodic ataxia type-1 mutations in the hKv1.1 cytoplasmic pore region alter the gating properties of the channel". EMBO J. 17 (5): 1200–7. doi:10.1093/emboj/17.5.1200. PMC   1170468 . PMID   9482717.
  14. 1 2 D'Adamo M, Imbrici P, Sponcichetti F, Pessia M (1999). "Mutations in the KCNA1 gene associated with episodic ataxia type-1 syndrome impair heteromeric voltage-gated K(+) channel function". FASEB J. 13 (11): 1335–45. doi: 10.1096/fasebj.13.11.1335 . PMID   10428758. S2CID   12876970.
  15. 1 2 Maylie B, Bissonnette E, Virk M, Adelman J, Maylie J (2002). "Episodic ataxia type 1 mutations in the human Kv1.1 potassium channel alter hKvbeta 1-induced N-type inactivation". J Neurosci. 22 (12): 4786–93. doi:10.1523/JNEUROSCI.22-12-04786.2002. PMC   6757728 . PMID   12077175.
  16. ↑ Knight M, Storey E, McKinlay Gardner R, Hand P, Forrest S (2000). "Identification of a novel missense mutation L329I in the episodic ataxia type 1 gene KCNA1--a challenging problem". Hum Mutat. 16 (4): 374. doi:10.1002/1098-1004(200010)16:4<374::AID-HUMU15>3.0.CO;2-4. PMID   11013453. S2CID   35501355.
  17. ↑ Lee H, Wang H, Jen J, Sabatti C, Baloh R, Nelson S (2004). "A novel mutation in KCNA1 causes episodic ataxia without myokymia". Hum Mutat. 24 (6): 536. doi: 10.1002/humu.9295 . PMID   15532032.
  18. ↑ Herson P, Virk M, Rustay N, Bond C, Crabbe J, Adelman J, Maylie J (2003). "A mouse model of episodic ataxia type-1". Nat Neurosci. 6 (4): 378–83. doi:10.1038/nn1025. PMID   12612586. S2CID   31227643.
  19. ↑ Manganas L, Akhtar S, Antonucci D, Campomanes C, Dolly J, Trimmer J (2001). "Episodic ataxia type-1 mutations in the Kv1.1 potassium channel display distinct folding and intracellular trafficking properties". J Biol Chem. 276 (52): 49427–34. doi: 10.1074/jbc.M109325200 . PMID   11679591.
  20. ↑ Green, M. C.; Sidman, R. L. (September 1962). "Tottering--a neuromusclar mutation in the mouse. And its linkage with oligosyndacylism". The Journal of Heredity. 53 (5): 233–237. doi:10.1093/oxfordjournals.jhered.a107180. ISSN   0022-1503. PMID   13950100.
  21. 1 2 3 4 van den Maagdenberg A, Kors E, Brunt E, van Paesschen W, Pascual J, Ravine D, Keeling S, Vanmolkot K, Vermeulen F, Terwindt G, Haan J, Frants R, Ferrari M (2002). "Episodic ataxia type 2. Three novel truncating mutations and one novel missense mutation in the CACNA1A gene". J Neurol. 249 (11): 1515–9. doi:10.1007/s00415-002-0860-8. PMID   12420090. S2CID   38913388.
  22. 1 2 Wan J, Khanna R, Sandusky M, Papazian D, Jen J, Baloh R (2005). "CACNA1A mutations causing episodic and progressive ataxia alter channel trafficking and kinetics". Neurology. 64 (12): 2090–7. doi:10.1212/01.WNL.0000167409.59089.C0. PMID   15985579. S2CID   5679518.
  23. ↑ Yue Q, Jen J, Nelson S, Baloh R (1997). "Progressive ataxia due to a missense mutation in a calcium-channel gene". Am J Hum Genet. 61 (5): 1078–87. doi:10.1086/301613. PMC   1716037 . PMID   9345107.
  24. 1 2 3 4 5 6 7 Denier C, Ducros A, Vahedi K, Joutel A, Thierry P, Ritz A, Castelnovo G, Deonna T, Gérard P, Devoize J, Gayou A, Perrouty B, Soisson T, Autret A, Warter J, Vighetto A, Van Bogaert P, Alamowitch S, Roullet E, Tournier-Lasserve E (1999). "High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2". Neurology. 52 (9): 1816–21. doi:10.1212/WNL.52.9.1816. PMID   10371528. S2CID   39421883.
  25. 1 2 Ophoff R, Terwindt G, Vergouwe M, van Eijk R, Oefner P, Hoffman S, Lamerdin J, Mohrenweiser H, Bulman D, Ferrari M, Haan J, Lindhout D, van Ommen G, Hofker M, Ferrari M, Frants R (1996). "Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4". Cell. 87 (3): 543–52. doi:10.1016/S0092-8674(00)81373-2. hdl: 1765/57576 . PMID   8898206. S2CID   16840573.
  26. ↑ Yue Q, Jen J, Thwe M, Nelson S, Baloh R (1998). "De novo mutation in CACNA1A caused acetazolamide-responsive episodic ataxia". Am J Med Genet. 77 (4): 298–301. doi:10.1002/(SICI)1096-8628(19980526)77:4<298::AID-AJMG9>3.0.CO;2-J. PMID   9600739.
  27. ↑ Guida S, Trettel F, Pagnutti S, Mantuano E, Tottene A, Veneziano L, Fellin T, Spadaro M, Stauderman K, Williams M, Volsen S, Ophoff R, Frants R, Jodice C, Frontali M, Pietrobon D (2001). "Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2". Am J Hum Genet. 68 (3): 759–64. doi:10.1086/318804. PMC   1274487 . PMID   11179022.
  28. ↑ Friend K, Crimmins D, Phan T, Sue C, Colley A, Fung V, Morris J, Sutherland G, Richards R (1999). "Detection of a novel missense mutation and second recurrent mutation in the CACNA1A gene in individuals with EA-2 and FHM". Hum Genet. 105 (3): 261–5. doi:10.1007/s004390051099. PMID   10987655.
  29. ↑ Tonelli A, D'Angelo M, Salati R, Villa L, Germinasi C, Frattini T, Meola G, Turconi A, Bresolin N, Bassi M (2006). "Early onset, non fluctuating spinocerebellar ataxia and a novel missense mutation in CACNA1A gene". J Neurol Sci. 241 (1–2): 13–7. doi:10.1016/j.jns.2005.10.007. PMID   16325861. S2CID   36806418.
  30. ↑ Denier C, Ducros A, Durr A, Eymard B, Chassande B, Tournier-Lasserve E (2001). "Missense CACNA1A mutation causing episodic ataxia type 2". Arch Neurol. 58 (2): 292–5. doi: 10.1001/archneur.58.2.292 . PMID   11176968.
  31. ↑ Steckley J, Ebers G, Cader M, McLachlan R (2001). "An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus". Neurology. 57 (8): 1499–502. doi:10.1212/wnl.57.8.1499. PMID   11673600. S2CID   27235962.
  32. ↑ Cader M, Steckley J, Dyment D, McLachlan R, Ebers G (2005). "A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia". Neurology. 65 (1): 156–8. doi:10.1212/01.wnl.0000167186.05465.7c. PMID   16009908. S2CID   29821321.
  33. ↑ Jen J, Wan J, Palos T, Howard B, Baloh R (2005). "Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures". Neurology. 65 (4): 529–34. doi:10.1212/01.WNL.0000172638.58172.5a. PMID   16116111. S2CID   22492395.
  34. ↑ de Vries B, Mamsa H, Stam AH, et al. (2009). "Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake". Arch. Neurol. 66 (1): 97–101. doi: 10.1001/archneurol.2008.535 . PMID   19139306.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.